Hypertensive phase and its association with surgical outcomes in Baerveldt implantation

Chansangpetch, Sunee; Surukrattanaskul, Supawan; Tapaneeyangkul, Paneeya; Tantisevi, Visanee

doi:10.1007/s10792-017-0654-8

Cited by 11 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding previous surgeries, particularly cataract surgery, we found that pseudophakic and aphakic eyes were less likely to develop HP. This finding contrasts with previous results, such as the studies by Chansangpetch et al ,[ 12 ] Duch et al ,[ 13 ] and Dubey et al . [ 5 ]…”

Section: Discussioncontrasting

confidence: 99%

“…4 ]. Similar findings are reported in eyes with BGI by Chansangpetch et al ,[ 12 ] which supports that HP could represent a form of early surgical failure and not a “phase,” as previously proposed by Nouri-Mahdavi and Caprioli. [ 3 ]…”

Section: Discussionsupporting

confidence: 91%

“…This has been attributed to an inherent limitation in AGV’s IOP reduction potential due to its valve mechanism and smaller surface area. [ 10 - 12 ] However, this contrasts with the study by Duch et al . [ 13 ] who found higher preoperative IOP to be a protective factor against HP.…”

Section: Discussioncontrasting

confidence: 56%

See 2 more Smart Citations

Prevalence of hypertensive phase and outcomes in patients with Ahmed valve implantation at one year of follow-up and evaluation of associated risk factors

Neaves-Mendez,

Hernandez-Oteyza,

Alvarez-Ascencio

et al. 2023

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To evaluate the prevalence of hypertensive phase (HP) and failure in patients who underwent Ahmed Glaucoma Valve (AGV) implantation and identify the possible risk factors for both HP and failure. Methods: A cross-sectional, observational study was conducted. Medical records of patients who underwent AGV implantation and had at least 1 year of follow-up were reviewed. HP was defined as an intraocular pressure (IOP) greater than 21 mmHg between the first week and the third postoperative month not attributable to other causes. Success was defined as an IOP between 6 and 21 mmHg, with preservation of light perception and no additional glaucoma surgeries. Statistical analysis was conducted to identify possible risk factors. Results: A total of 193 eyes of 177 patients were included. HP was present in 58%; a higher preoperative IOP and younger age were associated with HP. Pseudophakic or aphakic eyes had a lower HP rate. Failure was present in 29%; neovascular glaucoma, worse basal best corrected visual acuity (BCVA), higher baseline IOP, and postoperative complications were linked to a higher likelihood of failure. No difference in the HP rate between the failure and success groups was found. Conclusion: A higher baseline IOP and younger age are associated with HP development; pseudophakia and aphakia might be protective factors. Factors for AGV failure are a worse BCVA, neovascular glaucoma, postoperative complications, and a higher baseline IOP. At 1 year, a higher number of medications were needed to achieve IOP control in the HP group.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Prevalence of hypertensive phase and outcomes in patients with Ahmed valve implantation at one year of follow-up and evaluation of associated risk factors

Neaves-Mendez,

Hernandez-Oteyza,

Alvarez-Ascencio

et al. 2023

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…This may start after 10 days of surgery and persist up to 6 months requiring AGM for control of IOP. The subsequent reduction in bleb height, with step-down of AGM, or discontinuation, was defined as resolving or resolved HTP [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

The outcomes of a low-cost, non-valved glaucoma drainage device using mitomycin-C: 1-year results

Awad-Allah

Mousa

Ashour

2023

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To evaluate the indications, outcomes, and complications of the usage of Aurolab Aqueous Drainage Implant (AADI) using mitomycin-C. Methods A retrospective case series of patients who underwent AADI placement using mitomycin-C between April 2018 and June 2020 at Ain Shams University Hospitals, Cairo, Egypt. The data was extracted from the records of the patients with a minimum of 1 year of follow-up. Complete success was defined as IOP ≥ 5 mmHg and ≤ 21 mmHg or reduction of IOP by ≥ 20% from baseline without antiglaucoma medications (AGMs). Qualified success was defined as reaching the same IOP range with the aid of AGM. Results A total of 50 eyes of 48 patients were included. Neovascular glaucoma represented the commonest indication (13 patients, 26%). The mean preoperative IOP was 34.0 ± 7.1 mmHg, with a median number of AGM of 3 (mean ± SD = 2.84 ± 1), while the mean IOP after 12 months was 14.3 ± 4 with a median number of AGM of 0. (mean ± SD = 0.52 ± 0.89) (p < 0.001). Complete success was achieved in 33 patients (66%). Qualified success was achieved in 14 patients (28%). Thirteen eyes (26%) had variable postoperative complications; none of them required explantation of the device or affected the visual acuity (except one patient). Conclusion AADI with using mitomycin-C and ripcord during the surgery is an effective and relatively safe method of control of IOP in refractory and advanced cases of glaucoma, with an overall success rate of 94%.

show abstract

Ahmed ClearPath, PAUL Glaucoma Implant, and Aurolab Aqueous Drainage Implant

Fliney

Teng

Liu

et al. 2023

Current Practices in Ophthalmology

View full text Add to dashboard Cite

Hypertensive phase and its association with surgical outcomes in Baerveldt implantation

Cited by 11 publications

References 10 publications

Prevalence of hypertensive phase and outcomes in patients with Ahmed valve implantation at one year of follow-up and evaluation of associated risk factors

Prevalence of hypertensive phase and outcomes in patients with Ahmed valve implantation at one year of follow-up and evaluation of associated risk factors

The outcomes of a low-cost, non-valved glaucoma drainage device using mitomycin-C: 1-year results

Ahmed ClearPath, PAUL Glaucoma Implant, and Aurolab Aqueous Drainage Implant

Contact Info

Product

Resources

About